Maravai LifeSciences (NASDAQ:MRVI – Get Rating) had its price target decreased by analysts at Morgan Stanley from $49.00 to $35.00 in a research note issued to investors on Monday, Marketbeat reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 37.80% from the stock’s current price.
Several other research analysts have also recently commented on the company. Robert W. Baird lowered their target price on Maravai LifeSciences from $40.00 to $34.00 in a research note on Friday, August 5th. TheStreet cut Maravai LifeSciences from a “c-” rating to a “d+” rating in a research note on Tuesday, July 26th. Finally, The Goldman Sachs Group decreased their price target on Maravai LifeSciences from $44.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, July 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $43.20.
Maravai LifeSciences Trading Down 2.9 %
Shares of NASDAQ MRVI opened at $25.40 on Monday. Maravai LifeSciences has a twelve month low of $23.05 and a twelve month high of $63.55. The company has a current ratio of 7.14, a quick ratio of 6.55 and a debt-to-equity ratio of 0.80. The stock has a fifty day simple moving average of $27.75 and a 200-day simple moving average of $31.65. The stock has a market capitalization of $6.48 billion, a PE ratio of 15.57 and a beta of 0.54.
Institutional Trading of Maravai LifeSciences
Institutional investors and hedge funds have recently made changes to their positions in the company. Zions Bancorporation N.A. purchased a new stake in Maravai LifeSciences during the 1st quarter valued at approximately $28,000. SeaCrest Wealth Management LLC purchased a new stake in Maravai LifeSciences during the 2nd quarter valued at approximately $32,000. C M Bidwell & Associates Ltd. purchased a new stake in Maravai LifeSciences during the 1st quarter valued at approximately $38,000. Steward Partners Investment Advisory LLC raised its stake in Maravai LifeSciences by 6,670.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,354 shares of the company’s stock valued at $38,000 after acquiring an additional 1,334 shares during the last quarter. Finally, Arcadia Investment Management Corp MI purchased a new stake in Maravai LifeSciences during the 4th quarter valued at approximately $41,000. 50.18% of the stock is owned by hedge funds and other institutional investors.
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
